Pharmaceuticals, Healthcare, and Research by Bristol Myers Squibb
Bristol-Myers Squibb stock price forecast: short-term resistance holds as BMY slips 1.5%
Bristol-Myers Squibb is presenting the full Phase 3 SCOUT-HCM trial results at ACC26. The company says the data showcase a potential treatment option for adolescents with symptomatic obstructive ...
Neuroscience data release drives Bristol-Myers Squibb stock lower 1.50%
Bristol-Myers Squibb is presenting abstracts from its neuroscience portfolio at this year’s SIRS2026.The company’s presentation includes new data related to schizophrenia. Details are ...
Bristol-Myers Squibb stock price forecast: consolidation likely as BMY eyes upper range resistance
Bristol-Myers Squibb presented new clinical and real-world data in symptomatic obstructive hypertrophic cardiomyopathy at ACC26.The company stated these data build on its research. Results show ...
Bristol Myers Squibb wins U.S. FDA and European Commission approval for immunotherapy Hodgkin lymphoma treatment
Bristol Myers Squibb has received approval from both the U.S. FDA and the European Commission for its immunotherapy-based treatment combinations targeting classical Hodgkin lymphoma in certain ...
Bristol Myers Squibb gains FDA nod for multiple myeloma drug
Bristol Myers Squibb received a significant boost as the U.S. FDA accepted its New Drug Application for an investigational treatment for adult patients with relapsed or refractory multiple ...
Bristol Myers Squibb launches clinician education on FXIa research
Bristol Myers Squibb has announced the launch of a new educational campaign aimed at clinicians. The initiative focuses on underscoring the unmet needs in cardiovascular and thromboembolic care ...
